Posted inClinical Updates Wellness & Lifestyle
HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.